7 Cambridge Center<br>Cambridge Massachusetts 02
320 Charles Street
About Broad InstituteThe Broad Institute was launched to pioneer a new model of collaborative biomedical science that would transform medicine. To accomplish these goals, we have built an amazing team of talented “Broadies” who work together to realize this transformation.
We are always looking for new Broadies to join our team and help us tackle important problems at the cutting edge of science.
The Broad community The Broad community includes professional scientists from many disciplines, administrative staff, and students. We seek to cultivate an interdisciplinary, goal-oriented work environment that unleashes scientific creativity and empowers our people to pursue ambitious and critical projects
Our work transcends traditional academic boundaries, giving Broad employees and affiliates access to an unparalleled biomedical research community across the Harvard and MIT communities and beyond.
Benefits of working at Broad The Broad Institute is committed to providing its employees with a competitive compensation and benefits package. We recognize the need for our employees to have a balance between work and personal life. To that end, our benefit plans and options reflect our desire to promote an environment that supports the health, diversity, and general wellbeing of our employees.
All Broadies also have access to world-class research and state of the art technology and are fully supported in their professional development, pushing the envelope for further growth.
The Broad Benefits Program includes:
• Medical • Dental • Basic Life Insurance, Accidental Death & Dismemberment, Business Travel and Supplemental Life Insurance • Short-Term and Long-Term Disability • Flexible Spending Accounts • 401(K) Plan w/Competitive Employer Match • 4 Weeks of Vacation after 1 Year • Tuition Reimbursement • Identity Theft Prevention and Insurance • Estate Planning • Adoption Assistance • Employee Assistance Program (EAP) • MBTA Commuter Transportation Subsidies • Parents in a Pinch Back Up Child Care • Credit Union
The Broad Institute is an equal opportunity employer.
To learn more about the Broad’s job opportunities, visit our Career Center at: https://www.broadinstitute.org/careers/career-center
122 articles with Broad Institute
The Broad Institute of MIT and Harvard announced that renowned technologist, entrepreneur and philanthropist Eric Schmidt will become the next Chair of the Board of Directors, succeeding Louis V. Gerstner, Jr., who has served as Chair of the Board since 2013.
Broad Institute launches the Eric and Wendy Schmidt Center to connect biology, machine learning for understanding programs of life
Supported by a $150 million endowment from Eric and Wendy Schmidt, the center will create a new field of interdisciplinary research aimed at improving human health.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Broad Institute and Verily partner with Microsoft to accelerate the next generation of the Terra platform for health and life science research
Multiyear partnership brings together advanced technology, industry expertise and scale to help researchers interpret an unprecedented amount of biomedical data and derive insights to advance the treatment of human diseases
The Broad Institute is expanding its Cancer Dependency Map Consortium, an academic-industrial partnership program that was first announced last year.
Color and Researchers from Massachusetts General Hospital and the Broad Institute Discover Key Finding to Determine Risk of Genomic Diseases
The research, published August 20 in Nature Communications, unveils the relationship between monogenic variants and polygenic risk for coronary artery disease, breast cancer, and colorectal cancer.
Scientists at the Broad Institute of MIT and Harvard tested about 4,518 drugs on 578 human cancer cell lines. They discovered that almost 50 had previously unrecognized anti-cancer properties.
A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.
New framework simplifies and accelerates access to CRISPR intellectual property for research
ERS Genomics Provides Comment on New Patent Interference With the Broad Institute Relating to Invention of the CRISPR/Cas9 System
ERS Genomics Limited announced that the U.S. Patent and Trademark Office declared a patent interference between 10 separate patent applications owned by the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier, on the one hand, and 13 patents and one application held by the Broad Institute, Harvard University, and the Massachusetts Institute of Technology.
In the wake of the scandal caused by a Chinese researcher’s use of CRISPR-Cas9 gene editing to alter the DNA of embryos for seven couples, leading scientists called for a moratorium on heritable genome editing.
Research Roundup: Gene Therapy for Deafness, Autism Genes, Breakthroughs in Parkinson’s and ALS, ...
3/1/2019There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
New endeavor will advance blood-based biopsies and other technologies to speed cancer diagnosis and track patients' response to therapies
IBM Watson Health and the Broad Institute Launch Initiative to Help Clinicians Predict the Risk of Cardiovascular Disease with Genomics and AI
IBM Watson Health and the Broad Institute of MIT and Harvard are expanding their partnership to help clinicians better predict the possibility of serious cardiovascular diseases.
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
November 30 Research Roundup: CRISPR Embryos, Brain-Computer Interface, ADHD Genetic Variants and...
11/30/2018There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. Although most readers will already be aware of it, the biggest story, perhaps the biggest story of the year—certainly the most controversial—involves a Chinese researcher who used CRISPR to m...
11/29/2018Scientists from a consortium of prominent research institutions studied the entire genomes of more than 20,000 people with attention deficit/hyperactivity disorder (ADHD) and compared them to the genomes of 35,000 who did not have ADHD. They identified 12 genetic variants in the ADHD group, sugge...
Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
11/12/2018Biopharma companies name new members of their leadership teams. Who made big moves this week?
Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.